Cancelled by the investigator Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003079
- Lead Sponsor
- Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;
2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;
3) Inpatients aged 18 to 75 years male or female;
4) Volunteer to receive treatment under their own scheme and sign informed consent.
1) Patients with mild, severe or critical novel coronavirus disease;
2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;
3) Those who are allergic to the research drug and its main ingredients;
4) pregnant or lactating women;
5) Those who have difficulty taking medicine orally.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;lasting time of fever;
- Secondary Outcome Measures
Name Time Method Comparison of TCM symptom score (degree of fever, cough, sputum, chest tightness, shortness of breath, anorexia, abdominal distension, the tongue proper and the tongue coating, pulse condition);Clinical recovery time: the body temperature returned to normal and lasting for more than 3 days, the respiratory symptoms improved significantly, and the test result was negative for two consecutive times (ended at the time of the first negative result);Comparison of conversion rates of severe (severe or critical) subjects in each group;comparison of changes in SpO2, oxygen saturation, lymphocyte count;Comparison of changes in inflammation indicators (white blood cell count, C-reactive protein, ESR, procalcitonin) before and after treatment;